Why is Eli Lilly using non-GAAP financial measures?

Eli Lilly is using non-GAAP financial measures to provide investors with a clearer view of its ongoing operational performance. These measures exclude certain volatile or one-time items such as special charges, asset impairments, and other income/charges that can make it difficult to assess core business trends on a GAAP basis. The company believes these adjusted figures help in making more meaningful period-over-period comparisons.

What are some of the specific items adjusted for in the non-GAAP results?

Specific items adjusted for include a special charge related to the withdrawal of Xigris, an asset impairment charge for a delivery device platform, and other income resulting from the early payment of Amylin financial obligations. Restructuring charges from earlier in 2011 and 2012 are also excluded when comparing performance.

How should investors interpret these non-GAAP measures?

Investors should consider these non-GAAP measures in addition to, and not as a substitute for or superior to, measures prepared in accordance with GAAP. They are intended to help investors evaluate the company's ongoing operations and identify operating trends that might otherwise be masked by the excluded items.

LLY 8-K: Earnings & Results

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report Eli Lilly and Company's financial results for the third quarter and the first nine months of 2012. It also includes the company's financial expectations for the full year 2012.

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 24, 2012, to report its financial results for the third quarter and the first nine months of 2012. The filing primarily includes a press release detailing these results, with a significant focus on non-GAAP financial measures. Lilly utilizes these non-GAAP figures, which exclude specific charges and income items, to provide a clearer view of ongoing operational performance and facilitate meaningful period-over-period comparisons for investors. The report highlights several key adjustments made to GAAP figures, including charges related to the withdrawal of Xigris, an asset impairment on a delivery device platform, and significant other income from the early payment of Amylin financial obligations. Lilly emphasizes that these non-GAAP measures are intended to help investors evaluate core business performance and operating trends, separate from volatile or one-time events. The company also provided its financial expectations for 2012 on a non-GAAP basis, underscoring the importance of these adjusted metrics for understanding future performance.

Key Highlights

1Eli Lilly announced its third quarter and nine-month 2012 financial results via an 8-K filing on October 24, 2012.
2The filing primarily consists of a press release detailing the company's financial performance.
3Lilly provided results and guidance using non-GAAP financial measures, adjusting for significant items.
4Key adjustments mentioned include charges for Xigris withdrawal and an asset impairment, along with other income from Amylin debt settlement.
5The company believes non-GAAP measures offer valuable insights into ongoing operations and trends, distinct from GAAP reporting.
6Financial expectations for 2012, including earnings per share growth, were provided on a non-GAAP basis.

ELI LILLY & Co 8-K Report, Financial Results (Oct 24, 2012)

Summary

Key Highlights

Frequently Asked Questions